Navigation Links
Skinvisible Patent Granted in Australia
Date:6/3/2008

- Invisicare Patents Continue to be Granted Globally

LAS VEGAS, June 3 /PRNewswire-FirstCall/ -- Skinvisible, Inc. (OTC Bulletin Board: SKVI) (Website: http://www.skinvisible.com), the developers of Invisicare, a polymer delivery system that enhances topically applied products, has been granted a comprehensive patent in Australia. The Invisicare patent provides protection in the areas of "Topical Composition, Topical Composition Precursor, and Methods for Manufacturing and Using".

(Logo: http://www.newscom.com/cgi-bin/prnh/20030416/LAW068LOGO

http://www.newscom.com/cgi-bin/prnh/20040503/INVISICARELOGO )

This patent will assist Skinvisible's sales efforts in Australia by protecting its Invisicare technology and formulated products. Invisicare has a unique ability to hold active ingredients on the skin for extended periods of time while resisting wash-off, rub-off and perspiration. This benefit leads to additional unique enhancements to topical dermatology products. Additionally, Invisicare provides product life-cycle management by allowing for new patent protection for products coming off patent and providing improved claims to formulations of cosmetics, over-the-counter and prescription skincare products.

"The demand for our Invisicare technology and out products is international. A key component of our business strategy is to provide patentable products to our clients," said Mr. Terry Howlett, President and CEO of Skinvisible. "Having our Invisicare patent approved in Australia is one more degree of protection that we can provide to our international licensees. We continue to submit for patent protection worldwide for all products formulated with Invisicare."

Australia has followed India as the second international patent approved for Skinvisible. With numerous patents pending both for its technology and formulated products, Skinvisible continues to remain focused on securing licensees for its products internationally.

About Invisicare(R)

Skinvisible has patented its technology and trademarked its polymer delivery system Invisicare(R). Invisicare is a combination of hydrophilic and hydrophobic polymers that hold active ingredients on the skin for extended periods of time. They are non-occlusive and allow normal skin respiration and perspiration while moisturizing and protecting against exposure from a wide variety of environmental irritants. See: http://www.invisicare.com

About Skinvisible Pharmaceuticals, Inc.

Skinvisible Pharmaceuticals is a research-and-development company whose primary business objective is to license its proprietary formulations with Invisicare(R) to pharmaceutical and cosmeceutical companies as well as assisting companies in revitalizing or enhancing their existing skin care products. Skinvisible receives a combination of research and development fees, upfront license fees, and ongoing royalties for the life of the Invisicare patent. See: http://www.skinvisible.com

Forward-Looking Statements

This press release contains 'forward looking' statements within the meaning of Section 21A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and are subject to the safe harbors created thereby. Such statements involve certain risks and uncertainties associated with an emerging company. Actual results could differ materially from those projected in the forward looking statements as a result of risk factors discussed in Skinvisible, Inc. reports on file with the U.S. Securities and Exchange Commission (including, but not limited to, a report on Form 10Q for the quarter ending June 30, 2007).

Corporate Contact:

Terry Howlett, President/CEO

Skinvisible Pharmaceuticals, Inc.

Phone: 702-433-7154

Email: info@skinvisible.com


'/>"/>
SOURCE Skinvisible Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Dynavax Issued Landmark Patent Covering Second-Generation TLR9 Agonists
2. VisEn Medical Files Action to Invalidate New Caliper Life Sciences Patent
3. Pressure BioSciences, Inc. Issued First Patent in Canada
4. Oncolytics Biotech Inc. Announces Issuance of 23rd U.S. Patent
5. CODA Genomics Announces Issuance of Optimized Synthetic Gene Production Patent
6. Forest Laboratories Announces Federal Appeals Court Upholds Lexapro(R) Patent Decision
7. Weil Gotshal Wins Major Victory for Applera; Secures Summary Judgment Invalidating Three Patents
8. Angiotech receives favourable patent decision from New Zealands Intellectual Property Office
9. Angiotech reaches agreement with Johnson & Johnson to settle outstanding patent litigation
10. Warner Chilcott Announces New Information in USPTO Reexamination of Taclonex Patent
11. Intellect Neurosciences, Inc. Obtains Validation of European Patent for Alzheimers Vaccine in 19 Countries
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... HOUSTON , June 23, 2016 ... agreement with the Cy-Fair Sports Association to serve ... of the agreement, Houston Methodist Willowbrook will provide ... education and connectivity with association coaches, volunteers, athletes ... partner with the Cy-Fair Sports Association and to ...
(Date:6/23/2016)... FRANCISCO , June 23, 2016   EpiBiome ... has secured $1 million in debt financing from Silicon ... ramp up automation and to advance its drug development ... its new facility. "SVB has been an ... beyond the services a traditional bank would provide," said ...
(Date:6/23/2016)... , June 23, 2016 Apellis Pharmaceuticals, ... 1 clinical trials of its complement C3 inhibitor, ... and multiple ascending dose studies designed to assess ... of subcutaneous injection in healthy adult volunteers. ... either as a single dose (ranging from 45 ...
(Date:6/23/2016)... , ... June 23, 2016 , ... ... exhibiting at the Pennsylvania Convention Center and will showcase its product’s latest features ... will also be presenting a scientific poster on Disrupting Clinical Trials in The ...
Breaking Biology Technology:
(Date:4/28/2016)... First quarter 2016:   , Revenues amounted ... quarter of 2015 The gross margin was 49% (27) ... the operating margin was 40% (-13) Earnings per share ... operations was SEK 249.9 M (21.2) , Outlook   ... M. The operating margin for 2016 is estimated to ...
(Date:4/15/2016)... 2016  A new partnership announced today will ... decisions in a fraction of the time it ... high-value life insurance policies to consumers without requiring ... Force Diagnostics, rapid testing (A1C, Cotinine and HIV) ... pressure, weight, pulse, BMI, and activity data) available ...
(Date:3/31/2016)... 31, 2016   ... the "Company") LegacyXChange is excited to release ... soon to be launched online site for trading 100% ... ) will also provide potential shareholders a sense of ... to an industry that is notorious for fraud. The ...
Breaking Biology News(10 mins):